Skip to main content

Drug Interactions between cilastatin / imipenem / relebactam and IBgard

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

No interactions were found between cilastatin / imipenem / relebactam and IBgard. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

cilastatin / imipenem / relebactam

A total of 57 drugs are known to interact with cilastatin / imipenem / relebactam.

IBgard

A total of 22 drugs are known to interact with IBgard.

Drug and food/lifestyle interactions

Moderate

peppermint oil food/lifestyle

Applies to: IBgard (peppermint oil)

ADJUST DOSING INTERVAL: Administration of enteric-coated, gastro-resistant formulations of peppermint oil (e.g., delayed or sustained release capsules) with food may cause premature dissolution of the enteric coating and early release of the peppermint oil, which could lead to gastrointestinal irritation and reduced therapeutic effects.

MANAGEMENT: Enteric-coated, gastro-resistant formulations of peppermint oil should not be taken immediately after eating. These products should preferably be taken 30 to 90 minutes before a meal with water. The labeling for the specific product should be consulted for administration recommendations and other guidance.

References (3)
  1. (2018) "Product Information. Ibgard (peppermint oil)." IM Helthscience llc, 1
  2. (2021) "Product Information. Colpermin IBS Relief (peppermint oil)." Kenvue UK Ltd
  3. (2023) "Product Information. Buscomint (peppermint oil)." Opella Healthcare UK Ltd

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer